Rock Springs Capital Management’s Aimmune Therapeutics AIMT Stock Holding History

Rock Springs Capital Management’s Portfolio AIMT Stock Details AIMT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q2	–	Sell	-160,000	Closed	-$5.09M	–	155
2018 Q1	$5.09M	Sell	160,000 -133,000	-45%	-$4.68M	0.22%	118
2017 Q4	$11.1M	Hold	293,000	–	–	0.5%	70
2017 Q3	$7.26M	Hold	293,000	–	–	0.34%	87
2017 Q2	$6.02M	Hold	293,000	–	–	0.3%	90
2017 Q1	$6.37M	Hold	293,000	–	–	0.37%	77
2016 Q4	$5.99M	Hold	293,000	–	–	0.4%	72
2016 Q3	$4.39M	Hold	293,000	–	–	0.28%	95
2016 Q2	$3.17M	Hold	293,000	–	–	0.23%	104
2016 Q1	$3.97M	Buy	293,000 +33,354	+13%	+$520K	0.33%	88
2015 Q4	$4.79M	Buy	259,646 +59,646	+30%	+$1.1M	0.36%	90
2015 Q3	$5.06M	Buy	+200,000	New	+$4.68M	0.41%	81

Other funds holding AIMT

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

FCMI

Foresite Capital Management II Larkspur, California $29.2M AUM 44.84% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Aisling Capital New York $45.3M AUM 15.24% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

EAM

Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return

Rock Springs Capital Management's AIMT Position: Q2 2018 in Review

Rock Springs Capital Management sold out of Aimmune Therapeutics (AIMT) in Q2 2018, closing a stake of 160,000 shares — an estimated $5.09M sold.

Rock Springs Capital Management first reported a position in AIMT in Q3 2015 and held it in 11 quarters. The position peaked at $11.1M in Q4 2017. 151 funds tracked by Wall St. Rank hold AIMT as of Q2 2018.

Rock Springs Capital Management reported no remaining Aimmune Therapeutics position as of Q2 2018 after selling out during the quarter.
Rock Springs Capital Management sold 160,000 Aimmune Therapeutics shares in Q2 2018, an estimated $5.09M.
Rock Springs Capital Management first reported a position in Aimmune Therapeutics in Q3 2015 and held it in 11 quarters.
Rock Springs Capital Management's Aimmune Therapeutics position peaked at $11.1M in Q4 2017.
151 funds tracked by Wall St. Rank held Aimmune Therapeutics as of Q2 2018.

Based on Rock Springs Capital Management's 13F filing for Q2 2018, filed 14 Aug 2018.